On January 21, 2021 Sanofi announced its intention to sell its stake in Sanofi Bangladesh Limited (SBL) to Beximco Pharmaceuticals Limited, a leading and trusted pharmaceuticals company in Bangladesh.
The existing employees of Sanofi Bangladesh Limited may be reassured as Beximco Pharmaceuticals has granted a minimum of 3 years of job security and that all their compensation and benefits will remain the same moving forward, subject to compliance with existing SBL rules, regulations and labor laws of the country. In addition, Sanofi has also given employees the option to settle their end-term benefits, on an individual basis.
- Sanofi Bangladesh Limited will continue to operate in Bangladesh as a subsidiary of Beximco Pharmaceuticals Ltd., with Ministry of Industries (MoI) and Bangladesh Chemical Industries Corporation (BCIC) remaining as the other shareholders of the company.
- The employees will continue to hold their jobs.
- The Sanofi range of products including the global brands will also continue to be made available to patients in Bangladesh. Furthermore, Beximco Pharmaceuticals is keen to continue to build on Sanofi’s legacy through investments and growing the business to provide more patients with increased access to Sanofi’s products across Bangladesh.